European CHMP recommends approval of moxetumomab pasudotox (Lumoxiti) for treatment of relapsed or refractory hairy cell leukaemia

Moxetumomab pasudotox is a CD22-targeted immunotoxin designed to direct the cytotoxic action of the truncated Pseudomonas exotoxin to cells which express the CD22 receptor. Reported benefits includes ability to provide a durable response.

Source:

European Medicines Agency